Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Advances in Interventional Cardiology
    • Case Reports in Interventional Cardiology
    • Clinical Dilemmas in Cardiovascular Interventions
    • Contemporary Reviews in Interventional Cardiology
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation:
Cardiovascular Interventions

  • My alerts
  • Sign In
  • Join

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Advances in Interventional Cardiology
    • Case Reports in Interventional Cardiology
    • Clinical Dilemmas in Cardiovascular Interventions
    • Contemporary Reviews in Interventional Cardiology
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Original Article

Residual Ischemia After Revascularization in Multivessel Coronary Artery Disease

Insights From Measurement of Absolute Myocardial Blood Flow Using Magnetic Resonance Imaging Compared With Angiographic Assessment

Jayanth R. Arnold, Theodoros D. Karamitsos, William J. van Gaal, Luca Testa, Jane M. Francis, Paul Bhamra-Ariza, Ali Ali, Joseph B. Selvanayagam, Steve Westaby, Rana Sayeed, Michael Jerosch-Herold, Stefan Neubauer, Adrian P. Banning
Download PDF
https://doi.org/10.1161/CIRCINTERVENTIONS.112.000064
Circulation: Cardiovascular Interventions. 2013;6:237-245
Originally published June 18, 2013
Jayanth R. Arnold
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theodoros D. Karamitsos
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. van Gaal
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Testa
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane M. Francis
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Bhamra-Ariza
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Ali
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph B. Selvanayagam
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Westaby
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rana Sayeed
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Jerosch-Herold
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Neubauer
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian P. Banning
From the University of Oxford Centre for Clinical Magnetic Resonance Research, Department of Cardiovascular Medicine (J.R.A., T.D.K., J.M.F., P.B.-A., A.A., J.B.S., S.N.), Department of Cardiology (W.J.v.G., L.T., A.P.B.), and Department of Cardiothoracic Surgery (S.W., R.S.), John Radcliffe Hospital, Oxford, UK; and Brigham & Women’s Hospital & Harvard Medical School, Boston, MA (M.J.-H.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Background—Revascularization strategies for multivessel coronary artery disease include percutaneous coronary intervention and coronary artery bypass grafting. In this study, we compared the completeness of revascularization as assessed by coronary angiography and by quantitative serial perfusion imaging using cardiovascular magnetic resonance.

Methods and Results—Patients with multivessel coronary disease were recruited into a randomized trial of treatment with either coronary artery bypass grafting or percutaneous coronary intervention. Angiographic disease burden was determined by the Bypass Angioplasty Revascularization Investigation (BARI) myocardial jeopardy index. Cardiovascular magnetic resonance first-pass perfusion imaging was performed before and 5 to 6 months after revascularization. Using model-independent deconvolution, hyperemic myocardial blood flow was evaluated, and ischemic burden was quantified. Sixty-seven patients completed follow-up (33 coronary artery bypass grafting and 34 percutaneous coronary intervention). The myocardial jeopardy index was 80.7±15.2% at baseline and 6.9±11.3% after revascularization (P<0.0001), with revascularization deemed complete in 62.7% of patients. Relative to cardiovascular magnetic resonance, angiographic assessment overestimated disease burden at baseline (80.7±15.2% versus 49.9±29.2% [P<0.0001]), but underestimated it postprocedure (6.9±11.3% versus 28.1±33.4% [P<0.0001]). Fewer patients achieved complete revascularization based on functional criteria than on angiographic assessment (38.8% versus 62.7%; P=0.015). After revascularization, hyperemic myocardial blood flow was significantly higher in segments supplied by arterial bypass grafts than those supplied by venous grafts (2.04±0.82 mL/min per gram versus 1.89±0.81 mL/min per gram, respectively; P=0.04).

Conclusions—Angiographic assessment may overestimate disease burden before revascularization, and underestimate residual ischemia after revascularization. Functional data demonstrate that a significant burden of ischemia remains even after angiographically defined successful revascularization.

Clinical Trial Registration—URL:http://www.controlled-trials.com. Unique identifier:ISRCTN25699844.

  • bypass surgery
  • revascularization
  • stent

Introduction

Coronary artery bypass grafting (CABG) has historically been considered the revascularization standard for patients with multivessel and left main coronary artery stenosis. The results of percutaneous coronary intervention (PCI) have been improved by drug-eluting stent technology and, consequently, the potential indications for revascularization with PCI have expanded.1

A strategy of targeted or ischemia-driven revascularization is advocated in major guidelines.2 Untreated ischemia is an important determinant of an unfavorable outcome, and successful ischemia-driven revascularization improves prognosis.3,4 Recent studies examining the completeness of revascularization have demonstrated that residual ischemia after revascularization increases the risk of adverse outcomes after either PCI or CABG.5–13

Insights from physiological assessment using the pressure wire to measure fractional flow reserve have confirmed the limitation of angiography to assess the functional significance of coronary stenosis.14 Because the functional consequences of revascularization may not correlate precisely with angiographic appearances, a potential limitation of these previous studies examining completeness of revascularization is their reliance on angiographic measures.15

WHAT IS KNOWN

  • Revascularization strategies for multivessel coronary artery disease include percutaneous coronary intervention and coronary artery bypass grafting.

  • In large population–based studies, anatomic scores examining the completeness of revascularization have demonstrated that residual ischemia after revascularization increases the risk of adverse outcomes after either percutaneous coronary intervention or coronary artery bypass grafting.

WHAT THE STUDY ADDS

  • Functional data demonstrate that a significant burden of ischemia remains even after angiographically defined successful revascularization.

  • Angiographic assessment may underestimate residual ischemia after revascularization but overestimate disease burden before revascularization.

  • These data demonstrate the potential complementary role of cardiovascular magnetic resonance–based functional assessment in managing patients with complex coronary disease.

Cardiovascular magnetic resonance (CMR) provides an ideal modality to examine the functional status of the whole myocardium. Absolute quantification of myocardial blood flow using CMR benefits from high spatial resolution and reproducibility. Furthermore, this method permits detailed quantitative characterization of both the scale and spatial extent of ischemia, beyond the binary assessment afforded by visual techniques. In this study, we measured absolute myocardial blood flow to evaluate the completeness of revascularization and ischemia relief comprehensively in patients randomized to treatment with either CABG or PCI.

Methods

Study Design

Myocardial Injury following Coronary Artery Surgery versus Angioplasty (MICASA) is a prospective, single-center, randomized (1:1) trial comparing myocardial injury after PCI and CABG, ISRCTN25699844: http://www.controlled-trials.com/ISRCTN25699844. Methodology and results from this trial have been described previously.16,17 Differences in myocardial perfusion 6 months after PCI and CABG was a prespecified study comparison, approved by the Regional Institutional Ethics Committee. Written informed consent was obtained from each patient before enrollment.

Selection and Treatment of Patients

Patient selection, randomization, and revascularization procedures are fully described previously.17 In brief, patients referred for elective angiography for investigation of angina (stable or unstable) were recruited if they had 3-vessel (>50% stenoses) or 2-vessel coronary artery disease (including a type C left anterior descending and left main disease >50%), in whom it was determined that equivalent anatomic revascularization could be achieved with either PCI or CABG. Patients with no contraindication to perfusion imaging were studied (inclusion/exclusion criteria listed in Table 1). Subjects were treated with the intention of achieving complete revascularization of all vessels >1.5 mm in diameter with stenosis >50%, as defined by quantitative coronary angiography. Patients undergoing PCI were pretreated with dual antiplatelet therapy; post-PCI, clopidogrel was continued ≥12 months, and aspirin, indefinitely. The use of drug-eluting stents was the preferred strategy for all lesions. Patients undergoing CABG ceased antiplatelet agents ≥2 days before surgery. General anesthesia was administered according to standard practice, with coronary artery bypass using nonpulsatile flow and a membrane oxygenator. As is standard clinical practice in many cardiac centers, patients received ≥1 internal mammary artery graft. Post-CABG, aspirin was continued indefinitely.

View this table:
  • View inline
  • View popup
Table 1.

Patient Selection Criteria

Angiographic Assessment

Diagnostic angiograms were evaluated in a blinded manner, with scoring according to the SYNTAX score algorithm.18 The myocardial jeopardy index (MJI) was calculated using the Bypass Angioplasty Revascularization Investigation (BARI) score and using the Duke jeopardy score.19,20 Using the post-PCI angiographic appearances and the surgeon’s operative report in conjunction with the baseline angiogram for CABG, the postprocedure residual MJI (RMJI) was also calculated using both methods. Complete revascularization was defined as RMJI=0, mildly incomplete revascularization as RMJI>0 and <33%, and moderate-to-severe incomplete revascularization as RMJI>33%. Angiographic data were also evaluated in relation to the 17-segment AHA model and, using surgeon’s operative report, segments were characterized as to whether they had been revascularized, and whether the graft type was arterial or venous.21

CMR Procedures

Multiparametric CMR imaging (comprising assessment of myocardial perfusion and contractile function and late gadolinium enhancement [LGE]) was performed at 1.5-Tesla (Siemens Sonata) at baseline, and subsequently at 5 to 6 months after revascularization, corresponding to the standard interval for outcome assessment after PCI. Patients were instructed to avoid agents, which could antagonize the effects of adenosine (eg, caffeine, methylxanthines) for 24 hours before assessment.

For perfusion imaging, an ECG-gated T1-weighted fast gradient echo sequence was used (echo time, 1.04 ms; repetition time, 2 ms, saturation recovery time, 100 ms; voxel size, 2.1×2.6×8 mm3; flip angle, 17°) to acquire 3 short-axis images every heart beat (representing basal, midventricular, and apical segments) to track the first pass of a gadolinium-based contrast agent (0.04 mmol/kg intravenous bolus of Gadodiamide, Omniscan, GE Healthcare) injected at stress (after a 4-minute infusion of adenosine [140 μg/kg per minute]), and subsequently at rest (after 20 minutes). Patients were monitored by electrocardiography, sphygmomanometry, and pulse oximetry. For LGE imaging, after a further bolus of gadolinium (0.045 mmol/kg), images were acquired in the 3 long axes, and a short-axis stack using a T1-weighted segmented inversion-recovery turbo fast low-angle shot (turbo-FLASH) sequence (echo time, 4.8 ms; voxel size, 1.4×2.4×8 mm3; flip angle, 20°; interslice gap, 2 mm). For left ventricular (LV) function, steady-state free-precession cine images were acquired in the 3 long-axis views, and a short-axis stack (echo time/repetition time, 1.5/3.0 ms; flip angle, 60°; slice thickness, 7.0 mm, interslice, gap 3 mm).

All CMR images were analyzed in a masked fashion, presented in random order, for 16/17 segments (apical segment excluded) according to the 17-segment American Heart Association segmentation model.21 Processing time per case was 1 to 2 hours. For analysis of myocardial perfusion, signal intensity curves were generated by tracing endocardial and epicardial contours (MASS, Medis Medical Imaging Solutions, Leiden, The Netherlands), manually corrected for cardiac displacement. The myocardium was divided into equiangular segments (6 for basal and midventricular slices, and 4 for apical), and a region of interest placed at the center of the LV cavity to measure the arterial input of contrast, which was corrected for signal saturation by a contrast-enhancement calibration curve.22 Quantitative perfusion analysis was performed as previously described.23 Absolute myocardial blood flow (MBF) in mL/min per gram was calculated for each myocardial segment by model-independent deconvolution of myocardial signal intensity curves with the arterial input measured at the basal level.24,25 Segments with hyperemic MBF below 1.8 mL/min per gram were classified as ischemic.26 Ischemia burden was defined as the percentage of segments with ischemia. Complete revascularization at the patient level was defined as the absence of any residual ischemia at the segmental level after revascularization.

For analysis of LGE, areas of hyperenhancement were quantified using the full-width half maximum method (MASS, Medis Medical Imaging Solutions, Leiden, The Netherlands). For analysis of global LV function parameters, the short-axis steady-state free-precession images were analyzed using customized software (Syngo, Siemens, Erlangen, Germany), to determine end-diastolic volume index, end-systolic volume index, stroke volume index, ejection fraction, and mass index.

Statistical Analysis

Data analysis was performed using Medcalc version 9.1.0.1 (Mariakerke, Belgium) and R (version 2.10.1; R Foundation for Statistical Computing, Vienna, Austria; URL http://www.R-project.org). Deviation from normality was tested using the D’Agostino–Pearson test. Continuous data (without repeated measures) are presented as mean±SD, and groups were compared using t tests (paired where appropriate). Non-normally distributed data are presented as median (interquartile range), and nonpaired data were compared using the nonparametric Mann–Whitney U test, while paired measurements were compared with the Wilcoxon signed-rank test. The frequency distributions of categorical data were compared using McNemar tests, and χ2 test or Fisher exact test, as appropriate. Statistical tests were 2-tailed, and P<0.05 was considered significant.

The clinical end point was the composite of death/myocardial infarction/stroke/target lesion revascularization during up to 3 years of follow-up. Disease burden as assessed by CMR and by anatomic scoring methods (BARI, Duke scores) was compared within patients using 1-way repeated measures ANOVA.

For segmental perfusion analysis, involving repeated measures within each patient, linear mixed effect models were used to account for the within-patient correlation of segmental flows (nlme: Linear and Nonlinear Mixed Effects Models; R package version 3.1–92). Linear mixed effect models for segmental baseline and hyperemic blood flows were used to analyze: (1) changes in segmental hyperemic MBF on follow-up examination relative to baseline, and (2) the difference in hyperemic MBF between the 2 patient groups, and the interaction between these 2 effects.

In the linear mixed effects models for resting and hyperemic MBF, 2 data strata were considered. At the lowest level, MBF measurements in myocardial segments within the same patient shared a common, patient-specific random intercept component, but the intercept component varied between patients. At the patient level, all regression coefficients other than the intercept were fixed across the cohort, because there was no evidence that allowing a between-patient variation of the regression coefficients other than the intercept would lead to better agreement with the measured data.

Stepwise selection of predictors using Akaike information criterion was used to build more parsimonious linear mixed effect models for hyperemic myocardial blood flow. The candidate variables were the following: sex, age, body mass index, diabetes mellitus, family history of heart disease, hypertension, hyperlipidemia, smoking status, CMR examination/intervention effect with levels baseline and postintervention, patient management or intervention type (PCI or CABG). Stepwise forward and backward selections of candidate variables were used to select a model from this set of candidate variables. The final model for segmental hyperemic MBF included, besides patient management, examination time point, and presence of ischemia at baseline, also SYNTAX score (P=0.134), family history (P=0.011), resting MBF (P<1e-6), and age (P=0.0013).

To assess the impact of LGE on perfusion, hyperemic MBF was modeled with linear mixed effects model, using LGE transmurality (categorized by 3 levels) as single fixed-effects predictor. ANOVA was then applied for testing the variation across the 3 LGE transmurality levels (0%, 0%–50%, and 51%–100%).

Results

Study Participants

Of 72 participants recruited, 67 (93%) completed the full imaging protocol and were included in the final analysis (Figure 1). Five subjects did not undergo follow-up imaging (contraindication to gadolinium administration in 1, failure of Gadolinium first-pass in 1, and 3 subjects declined follow-up perfusion imaging). One patient was randomized to PCI but received CABG, because of failed PCI (inability to pass a wire beyond a chronic total occlusion); in the perfusion analysis, this patient was included in the CABG cohort.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Consort statement flow diagram of recruited subjects. CABG indicates coronary artery bypass grafting; CMR, cardiovascular magnetic resonance; PCI, percutaneous coronary intervention; and TLR, target lesion revascularization.

Patients in the 2 groups were matched with regard to most baseline demographic and clinical characteristics (Table 2). The median time between randomization and treatment was 33days (5–55) for PCI and 20 days (13–73) for CABG (P=0.22). Follow-up imaging was performed at a median of 188 days (171–213) after revascularization in the CABG group and at 182 days (162–195) in the PCI group (P=0.21). All CMR images were of sufficient quality for analysis, and no images were excluded.

View this table:
  • View inline
  • View popup
Table 2.

Baseline Clinical Characteristics

Procedural Data

In the PCI group, 34 patients underwent PCI to 85 vessels (2.50 treated vessels per patient), using 142 stents (1.67 stents per vessel). Patients undergoing PCI received an average of 4.3±1.6 stents (total stent length 79.9±29.8 mm per patient). Aside from 1 lesion, all vessels were treated with drug-eluting stents. The median procedure time was 60.5 minutes (46–83). The procedure was uncomplicated in 31 cases; occlusive dissection occurred in 3, and was successfully managed percutaneously in all 3 cases.

In the CABG group, 33 patients underwent on-pump CABG using 80 grafts (2.42 grafts per patient). Conduit material used for grafting comprised 33 left internal mammary grafts, 45 saphenous vein grafts, and 2 free arterial grafts. The average time on bypass was 56.3±21.7 minutes, with cross-clamp time of 34.6±12.8 minutes.

Angiographic Assessment of Disease Burden and Completeness of Revascularization

In the 67 patients who completed the imaging protocol, the mean MJI (BARI) was 80.7±15.2% at baseline and 6.9±11.3% after revascularization (P<0.0001). The MJI was comparable in both groups at baseline (82.6±16.0% for PCI versus 78.8±14.4% for CABG; P=0.31) and postrevascularization (6.4±12.0% versus 7.4±10.7%, respectively; P=0.73). According to the BARI score, complete revascularization was achieved in 63% of subjects (60.6% of the CABG group and 65% of the PCI group; P=0.92), with 33% having 0% to 33% residual ischemia and 4.5% having >33% residual ischemia postrevascularization. Complete results and jeopardy index data derived from the Duke score are presented in Table 3 and Figure 2. Relative to the BARI score, the mean Duke score was lower at baseline (BARI 80.7±15.2% versus Duke 64.5±29.6%; P=0.0001) but comparable postprocedure (BARI 6.9±11.3% versus Duke 6.8±12.7%; P=0.99)

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Myocardial ischemia burden postrevascularization as determined by anatomic and functional measures by revascularization strategy. Figure denotes percentage of patients in each category of residual ischemia burden/myocardial jeopardy index category as defined by BARI, Duke, and cardiovascular magnetic resonance (CMR) for percutaneous coronary intervention (PCI) vs coronary artery bypass grafting (CABG). BARI indicates Bypass Angioplasty Revascularization Investigation.

View this table:
  • View inline
  • View popup
Table 3.

Myocardial Ischemia Burden as Determined by Anatomic and Functional Measures

Functional Assessment of Ischemia Burden and Completeness of Revascularization

Ischemia burden as determined by CMR was 49.9±29.2% at baseline and 28.1±33.4% after revascularization (P<0.0001). Based on CMR criteria, complete revascularization was achieved in 39% of subjects, with 27% having 0% to 33% residual ischemia and 34% having >33% ischemic segments at follow-up.

Compared with CMR-determined ischemic burden, both angiographic scores overestimated disease burden at baseline (CMR 49.9±29.2% versus BARI 80.7±15.2% [P<0.0001] and Duke 64.5±29.6% [P=0.0019]; Table 3). However, postprocedure, both angiographic scores significantly underestimated residual ischemia (CMR 28.1±33.4% versus BARI 6.9±11.3% [P<0.0001] and Duke 6.8±12.7% [P<0.0001]).

Clinical Outcomes

Three-year clinical follow-up was available in 100% of subjects. At 3 years postrevascularization (2.5 years after second CMR evaluation), there were 11 end points (1 death, 1 myocardial infarction, and 9 repeat revascularizations—6/34 PCI (18%) and 5/33 (15%) CABG (P=0.96). Before the second CMR assessment at 6 months, the composite end point occurred in 5 patients (1 myocardial infarction and 1 repeat revascularization in the CABG group, and 3 repeat revascularizations in the PCI group). After the second CMR scan, the composite end point occurred in 6 patients (1 death and 2 repeat revascularization in the CABG group, and 3 repeat revascularizations in the PCI group).

Effect of Revascularization on Segmental Myocardial Perfusion

Perfusion data for a total of 1072 myocardial segments were available. Because of the confounding influence of LGE on myocardial perfusion, segments with LGE at baseline (n=118; 11%) were excluded from this analysis. Of the remaining segments, 47% were deemed ischemic at baseline and 53% nonischemic.

In segments that were nonischemic at baseline (n=222 for CABG and n=277 for PCI), there was no significant change in hyperemic MBF after revascularization (2.40±0.46 mL/min per gram at baseline and 2.51±0.75 mL/min per gram postrevascularization [P=0.17]). At each time point, there was no significant difference in hyperemic MBF between the 2 groups (at baseline 2.44±0.53 for CABG versus 2.36±0.40 for PCI, P=0.80, and postrevascularization, 2.50±0.75 versus 2.51±0.77, respectively; P=0.26).

In segments that were ischemic at baseline (n=230 for CABG and n=223 for PCI), there was no significant difference in baseline hyperemic MBF (1.22±0.34 mL/min per gram in the CABG group, and 1.26±0.36 mL/min per gram in the PCI group; P=0.26; Figure 3). After revascularization, there was a significant increase in MBF both for CABG (from 1.20±0.33 mL/min per gram to 1.97±0.79 mL/min per gram; P<0.0001) and for PCI (from 1.23±0.34 mL/min per gram to 2.38±0.78 mL/min per gram; P<0.0001). However, hyperemic MBF was significantly higher after PCI than post-CABG (P=0.0002; Figure 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Segmental hyperemic MBF before and after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in segments with ischemia at baseline. Segmental hyperemic MBF in ischemic segments without late gadolinium enhancement at baseline (ischemia defined as hyperemic MBF<1.8). Hyperemic MBF did not differ significantly between the 2 patient groups before revascularization (P=0.47) but was higher after PCI (P=0.003). MBF indicates myocardial blood flow.

If the 5 subjects who underwent repeat revascularizationbefore their follow-up CMR assessment, hyperemic MBF postrevascularization remained higher post-PCI (2.37±0.78 mL/min per gram [n=207 segments]) compared with post-CABG (1.96±0.80 mL/min per gram, [n=220 segments]; P=0.003).

Effect of Revascularization on Ischemia Burden

With exclusion of the 5 subjects who underwent repeat revascularization before their follow-up CMR assessment, at baseline, 44% of segments in the CABG group (220/496) were fully viable but deemed ischemic, and 42% (207/496) in the PCI group (P=0.44). After revascularization, 40% of these segments in the CABG group (89/220) and 24% in the PCI group (50/207) remained ischemic (P=0.0005). At the patient level, (n=31 for CABG and n=31 for PCI), percentage ischemic myocardium was 56.5% (95% confidence interval [CI], 45.2%–67.6%) in the CABG group at baseline and 45.6% (CI, 35.2%–55.9%) in the PCI group (P=0.15). After revascularization, percentage ischemic myocardium was 36.5% (CI, 22.8%–50.2%) and 18.6% (CI, 9.0%–28.0%), respectively (P=0.03). After revascularization, complete revascularization was achieved in 54.8% (17/31) of PCI patients compared with 25.8% (8/31) of CABG patients (P=0.038).

Impact of Graft Type and LGE on Segmental Perfusion

Analysis of the types of graft vessel used in the CABG cohort revealed that at baseline, there was no significant difference in MBF in segments subsequently revascularized by arterial or venous grafts (1.18±0.34 mL/min per gram versus 1.23±0.35 mL/min per gram, respectively; P=0.67). However, postrevascularization, hyperemic MBF was significantly higher in segments supplied by arterial grafts than those supplied by venous grafts (2.04±0.82 mL/min per gram versus 1.89±0.81 mL/min per gram, respectively; P=0.04; Figure 4).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Segmental hyperemic MBF before and after coronary artery bypass grafting (CABG) according to graft type. Hyperemic MBF did not differ significantly between the 2 groups before revascularization (P=0.67) but was higher after CABG in segments subtended by arterial grafts (P=0.04). MBF indicates myocardial blood flow.

In segments with LGE, hyperemic myocardial blood flow declined with increasing LGE transmurality, both at baseline and after revascularization (Figure 5). Even in segments with significant scar burden at baseline, there was evidence of improvement in hyperemic MBF after revascularization.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Hyperemic MBF in segments with increasing late gadolinium enhancement (LGE) transmurality at baseline and postrevascularization. Hyperemic MBF declined significantly with the transmurality of LGE, both at baseline and after revascularization. MBF indicates myocardial blood flow.

Effect of Revascularization on Global LV Indices

Baseline LV systolic function was well preserved in both groups (ejection fraction 67±11% for CABG and 70±8% for PCI; P=0.13). After revascularization, there were no significant changes in ejection fraction, left ventricular end-systolic volume, and left ventricular end-diastolic volume, and no differences between the 2 cohorts (data not shown).

Discussion

This study compares existing anatomic scores reflecting the completeness of revascularization and absolute functional measurement of myocardial blood flow derived by CMR. Relative to functional assessment, angiographic scoring systems overestimate the degree of disease burden before revascularization and systematically underestimate the degree of residual ischemia after revascularization. These data demonstrate the potential complementary role of CMR-based functional assessment both before and possibly after revascularization, in patients with complex coronary disease.

The use of CMR perfusion imaging in our study enabled an in-depth and detailed quantitative characterization of ischemia, identifying not only the spatial extent of ischemia, but also the scale of the hyperemic response of that territory. Historically, the assessment of the functional consequences of obstructive coronary disease has required additional stress imaging after diagnostic coronary angiography. Insights from measurement of fractional flow reserve have shown that the significance of discrete lesions on angiography tends to be overestimated, and long diffuse lesions can be functionally significant but underestimated by angiography. These insights have direct implications when planning revascularization strategies as demonstrated by the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) study, where use of fractional flow reserve to identify ischemia resulted in improved clinical outcomes using fewer coronary stents.4

In this study, both the BARI and Duke angiographic scores overestimated the extent of ischemia at baseline and underestimated it postrevascularization. By their nature, these scores assume a perfect procedural result after revascularization, which inevitably cannot always be delivered in the real world. Assessment of perfusion in this study occurred 6 months after revascularization. The hemodynamic results of PCI may be compromised by procedural complications and limited stent expansion and incomplete lesion coverage. Subsequent restenosis and nonculprit lesion progression are also possible causes of reduced myocardial perfusion. Graft occlusion after CABG occurs most frequently within the first few months of the procedure. Venous graft occlusion may be clinically occult but will obviously impair myocardial perfusion in the dependent territory.

Despite their inherent limitations, both anatomic scores are well established and, in large population–based studies, both scores have demonstrated the negative impact of residual nonrevascularized myocardium on long-term prognosis after both PCI and CABG.5–13 Our preliminary data suggest potential for larger comparative studies of CMR-based functional assessment with these existing anatomic scores. This could potentially result in a more accurate risk prediction in the individual patient after revascularization.

Another advantage of using multiparametric CMR with LGE imaging is its potential to incorporate concurrent viability assessment. Using LGE imaging in this study, the tissue response to revascularization in ischemic territories was assessed, whereas avoiding the confounding influence of scar (which cannot be achieved with most alternative imaging modalities). Demonstrable LGE has been shown to have an adverse prognostic impact before revascularization, and previous studies have also shown that, at a segmental level, the likelihood of functional improvement after revascularization declines with increasing LGE transmurality.27 However, previous studies have not assessed the relationship between LGE and myocardial perfusion. Our data demonstrate that the extent of the hyperemic response declines with increasing LGE transmurality. This is probably predictable, but it is noteworthy that revascularization augmented hyperemic MBF even in those segments with significant scar burden at baseline, which previously have been considered unworthy of revascularization. This suggests that revascularizing hypoperfused segments with some evidence of viability might be beneficial for the purpose of reducing the overall ischemic myocardial burden.

Our data provide a clear demonstration that arterial grafting achieves greater augmentation of flow in response to hyperemia than a venous conduit. The ability of arteries to dilate in response to increased demand is well recognized. Clinical data suggests improved longevity and better clinical outcomes after revascularization using internal mammary arteries.28 Despite this, revascularization with a single mammary artery and ≥2 veins is the standard practice in most cardiac surgical centers. Our data provide further support that complete revascularization with arterial grafts should be considered as the surgical technique of choice.

As anticipated, patients randomized to either CABG or PCI experienced a significant improvement in myocardial perfusion in ischemic territories. However, the scale of the hyperemic response after revascularization with PCI was greater than after CABG using mixed arterial and venous grafts. One potential explanation for this result is that restoring patency to native coronary arteries permits higher blood flow than the alternative strategy of diverting blood through a bypass conduit, with the consequences of competitive retrograde flow. Secondly, in the context of complex coronary artery disease, PCI has the potential to provide complete revascularization to the whole distribution of an epicardial vessel with multiple lesions in series. By contrast, bypass with a single graft may reperfuse only the distal segment, leaving areas upstream from the stenosis untreated, and this myocardium is left potentially ischemic. However, it must be noted that these data reflect a snapshot of revascularization at 6 months after the procedure. There is little doubt that despite advances in coronary stent technology, bypass surgery still provides a more durable clinical result in patients with diffuse coronary disease particularly if they are diabetic.29

Limitations

Our study is restricted by the small number of subjects involved, but it serves the purpose of hypothesis generation for larger future studies, which might characterize appropriate prognosis-defining thresholds of ischemia and to examine whether the achievement of higher hyperemic flows might improve clinical outcome. In our study, we defined ischemia as the presence of a perfusion deficit, which is an established and sensitive indicator of ischemia, most commonly used in clinical practice and, the presence of ischemia, as indicated by perfusion deficits, is also a strong predictor of future clinical events.30,31 We did not assess other, cellular, consequences of ischemia, such as ECG changes or wall motion abnormalities.

Currently, there are limited published data involving CMR regarding the appropriate threshold to define ischemia and, although absolute perfusion CMR has been extensively validated, there are limited data on its use after CABG.26,32,33 In this study, we used a hyperemic myocardial blood flow threshold of 1.8 mL/min per gram, which, in a previous study, was defined and then prospectively validated.26 Previous studies using CMR perfusion have used myocardial perfusion reserve index, a ratio of hyperemic to resting flow.32,33 However, using this approach, small changes in resting perfusion can have a disproportionate effect on myocardial perfusion reserve index, and correction by rate-pressure product (which only 1 of these studies used) may be incomplete. We also used model-independent deconvolution, which enables an accurate representation of the physiological impulse response, free from assumptions regarding its shape or compartmental structure.

Conclusions

Angiographic estimation of the completeness of revascularization may overestimate disease burden at baseline and underestimate residual disease after revascularization. Functional data demonstrate that a significant burden of ischemia remains even after apparently successful revascularization. The use of functional techniques may help improve our understanding of the impact of incomplete revascularization on long-term cardiovascular outcomes and facilitate the assessment of residual disease after revascularization and clinical decision making regarding the choice of revascularization strategy.

Acknowledgments

The authors are grateful to Dr C. Antoniades for statistical support.

Sources of Funding

This work was supported by the British Heart Foundation, the UK Medical Research Council, and the Oxford NIHR Biomedical Research Center. Contributions to the cost of the study were made by unrestricted research donation from both Cordis, a Johnson & Johnson Company, and Boston Scientific Corp.

Disclosures

Prof Neubauer is supported by the Oxford British Heart Foundation Center of Research Excellence. Prof Banning has received honoraria from Abbott Vascular, Cordis, a Johnson & Johnson Company, and Boston Scientific Corp.

Footnotes

  • Guest Editor for this article was Theodore A. Bass, MD.

  • Received August 22, 2012.
  • Accepted March 21, 2013.
  • © 2013 American Heart Association, Inc.

References

  1. 1.↵
    1. Stettler C,
    2. Wandel S,
    3. Allemann S,
    4. Kastrati A,
    5. Morice MC,
    6. Schömig A,
    7. Pfisterer ME,
    8. Stone GW,
    9. Leon MB,
    10. de Lezo JS,
    11. Goy JJ,
    12. Park SJ,
    13. Sabaté M,
    14. Suttorp MJ,
    15. Kelbaek H,
    16. Spaulding C,
    17. Menichelli M,
    18. Vermeersch P,
    19. Dirksen MT,
    20. Cervinka P,
    21. Petronio AS,
    22. Nordmann AJ,
    23. Diem P,
    24. Meier B,
    25. Zwahlen M,
    26. Reichenbach S,
    27. Trelle S,
    28. Windecker S,
    29. Jüni P
    . Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Kern MJ,
    2. Lerman A,
    3. Bech JW,
    4. De Bruyne B,
    5. Eeckhout E,
    6. Fearon WF,
    7. Higano ST,
    8. Lim MJ,
    9. Meuwissen M,
    10. Piek JJ,
    11. Pijls NH,
    12. Siebes M,
    13. Spaan JA
    ; American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. Circulation. 2006;114:1321–1341.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Shaw LJ,
    2. Berman DS,
    3. Maron DJ,
    4. Mancini GB,
    5. Hayes SW,
    6. Hartigan PM,
    7. Weintraub WS,
    8. O’Rourke RA,
    9. Dada M,
    10. Spertus JA,
    11. Chaitman BR,
    12. Friedman J,
    13. Slomka P,
    14. Heller GV,
    15. Germano G,
    16. Gosselin G,
    17. Berger P,
    18. Kostuk WJ,
    19. Schwartz RG,
    20. Knudtson M,
    21. Veledar E,
    22. Bates ER,
    23. McCallister B,
    24. Teo KK,
    25. Boden WE
    ; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–1291.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Tonino PA,
    2. De Bruyne B,
    3. Pijls NH,
    4. Siebert U,
    5. Ikeno F,
    6. van’ t Veer M,
    7. Klauss V,
    8. Manoharan G,
    9. Engstrøm T,
    10. Oldroyd KG,
    11. Ver Lee PN,
    12. MacCarthy PA,
    13. Fearon WF
    ; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213–224.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Bell MR,
    2. Gersh BJ,
    3. Schaff HV,
    4. Holmes DR Jr.,
    5. Fisher LD,
    6. Alderman EL,
    7. Myers WO,
    8. Parsons LS,
    9. Reeder GS
    . Effect of completeness of revascularization on long-term outcome of patients with three-vessel disease undergoing coronary artery bypass surgery. A report from the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1992;86:446–457.
    OpenUrlAbstract/FREE Full Text
  6. 6.
    1. Bourassa MG,
    2. Yeh W,
    3. Holubkov R,
    4. Sopko G,
    5. Detre KM
    . Long-term outcome of patients with incomplete vs complete revascularization after multivessel PTCA. A report from the NHLBI PTCA Registry. Eur Heart J. 1998;19:103–111.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Ellis SG,
    2. Chew D,
    3. Chan A,
    4. Whitlow PL,
    5. Schneider JP,
    6. Topol EJ
    . Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation. 2002;106:1205–1210.
    OpenUrlAbstract/FREE Full Text
  8. 8.
    1. Hannan EL,
    2. Racz M,
    3. Holmes DR,
    4. King SB III.,
    5. Walford G,
    6. Ambrose JA,
    7. Sharma S,
    8. Katz S,
    9. Clark LT,
    10. Jones RH
    . Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation. 2006;113:2406–2412.
    OpenUrlAbstract/FREE Full Text
  9. 9.
    1. Hannan EL,
    2. Wu C,
    3. Walford G,
    4. Holmes DR,
    5. Jones RH,
    6. Sharma S,
    7. King SB III.
    . Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. J Am Coll Cardiol Cardiovasc Interv. 2009;2:17–25.
    OpenUrl
  10. 10.
    1. Nikolsky E,
    2. Gruberg L,
    3. Patil CV,
    4. Roguin A,
    5. Kapeliovich M,
    6. Petcherski S,
    7. Boulos M,
    8. Grenadier E,
    9. Amikam S,
    10. Linn S,
    11. Markiewicz W,
    12. Beyar R
    . Percutaneous coronary interventions in diabetic patients: is complete revascularization important? J Invasive Cardiol. 2004;16:102–106.
    OpenUrlPubMed
  11. 11.
    1. Tamburino C,
    2. Angiolillo DJ,
    3. Capranzano P,
    4. Dimopoulos K,
    5. La Manna A,
    6. Barbagallo R,
    7. Tagliareni F,
    8. Mangiafico S,
    9. Guzman LA,
    10. Galassi AR,
    11. Bass TA
    . Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents. Catheter Cardiovasc Interv. 2008;72:448–456.
    OpenUrlCrossRefPubMed
  12. 12.
    1. van den Brand MJ,
    2. Rensing BJ,
    3. Morel MA,
    4. Foley DP,
    5. de Valk V,
    6. Breeman A,
    7. Suryapranata H,
    8. Haalebos MM,
    9. Wijns W,
    10. Wellens F,
    11. Balcon R,
    12. Magee P,
    13. Ribeiro E,
    14. Buffolo E,
    15. Unger F,
    16. Serruys PW
    . The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol. 2002;39:559–564.
    OpenUrlCrossRefPubMed
  13. 13.
    1. Wu C,
    2. Dyer AM,
    3. King SB III.,
    4. Walford G,
    5. Holmes DR Jr.,
    6. Stamato NJ,
    7. Venditti FJ,
    8. Sharma SK,
    9. Fergus I,
    10. Jacobs AK,
    11. Hannan EL
    . Impact of incomplete revascularization on long-term mortality after coronary stenting. Circ Cardiovasc Interv. 2011;4:413–421.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. De Bruyne B,
    2. Baudhuin T,
    3. Melin JA,
    4. Pijls NH,
    5. Sys SU,
    6. Bol A,
    7. Paulus WJ,
    8. Heyndrickx GR,
    9. Wijns W
    . Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography. Circulation. 1994;89:1013–1022.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Uren NG,
    2. Melin JA,
    3. De Bruyne B,
    4. Wijns W,
    5. Baudhuin T,
    6. Camici PG
    . Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med. 1994;330:1782–1788.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Lim CC,
    2. van Gaal WJ,
    3. Testa L,
    4. Cuculi F,
    5. Arnold JR,
    6. Karamitsos T,
    7. Francis JM,
    8. Petersen SE,
    9. Digby JE,
    10. Westaby S,
    11. Antoniades C,
    12. Kharbanda RK,
    13. Burrell LM,
    14. Neubauer S,
    15. Banning AP
    . With the “universal definition,” measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol. 2011;57:653–661.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. van Gaal WJ,
    2. Arnold JR,
    3. Testa L,
    4. Karamitsos T,
    5. Lim CC,
    6. Ponnuthurai FA,
    7. Petersen S,
    8. Francis JM,
    9. Selvanayagam J,
    10. Sayeed R,
    11. West N,
    12. Westaby S,
    13. Neubauer S,
    14. Banning AP
    . Myocardial injury following coronary artery surgery versus angioplasty (MICASA): a randomised trial using biochemical markers and cardiac magnetic resonance imaging. EuroIntervention. 2011;6:703–710.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Sianos G,
    2. Morel MA,
    3. Kappetein AP,
    4. Morice MC,
    5. Colombo A,
    6. Dawkins K,
    7. van den Brand M,
    8. Van Dyck N,
    9. Russell ME,
    10. Mohr FW,
    11. Serruys PW
    . The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219–227.
    OpenUrlPubMed
  19. 19.↵
    1. Alderman EL,
    2. Stadius M
    . The angiographic definitions of the Bypass Angioplasty Revascularization Investigation. Coron Artery Dis. 1992;3:1189–1207.
    OpenUrl
  20. 20.↵
    1. Califf RM,
    2. Phillips HR III.,
    3. Hindman MC,
    4. Mark DB,
    5. Lee KL,
    6. Behar VS,
    7. Johnson RA,
    8. Pryor DB,
    9. Rosati RA,
    10. Wagner GS
    . Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol. 1985;5:1055–1063.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Cerqueira MD,
    2. Weissman NJ,
    3. Dilsizian V,
    4. Jacobs AK,
    5. Kaul S,
    6. Laskey WK,
    7. Pennell DJ,
    8. Rumberger JA,
    9. Ryan T,
    10. Verani MS
    ; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539–542.
    OpenUrlFREE Full Text
  22. 22.↵
    1. Jerosch-Herold M
    . Quantification of myocardial perfusion by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:57.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Petersen SE,
    2. Jerosch-Herold M,
    3. Hudsmith LE,
    4. Robson MD,
    5. Francis JM,
    6. Doll HA,
    7. Selvanayagam JB,
    8. Neubauer S,
    9. Watkins H
    . Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418–2425.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Arnold JR,
    2. Francis JM,
    3. Karamitsos TD,
    4. Lim CC,
    5. van Gaal WJ,
    6. Testa L,
    7. Bhamra-Ariza P,
    8. Selvanayagam JB,
    9. Sayeed R,
    10. Westaby S,
    11. Banning AP,
    12. Neubauer S,
    13. Jerosch-Herold M
    . Myocardial perfusion imaging after coronary artery bypass surgery using cardiovascular magnetic resonance: a validation study. Circ Cardiovasc Imaging. 2011;4:312–318.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Jerosch-Herold M,
    2. Swingen C,
    3. Seethamraju RT
    . Myocardial blood flow quantification with MRI by model-independent deconvolution. Med Phys. 2002;29:886–897.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Arnold JR,
    2. Karamitsos TD,
    3. Bhamra-Ariza P,
    4. Francis JM,
    5. Searle N,
    6. Robson MD,
    7. Howells RK,
    8. Choudhury RP,
    9. Rimoldi OE,
    10. Camici PG,
    11. Banning AP,
    12. Neubauer S,
    13. Jerosch-Herold M,
    14. Selvanayagam JB
    . Myocardial oxygenation in coronary artery disease: insights from blood oxygen level-dependent magnetic resonance imaging at 3 tesla. J Am Coll Cardiol. 2012;59:1954–1964.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Kim RJ,
    2. Wu E,
    3. Rafael A,
    4. Chen EL,
    5. Parker MA,
    6. Simonetti O,
    7. Klocke FJ,
    8. Bonow RO,
    9. Judd RM
    . The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–1453.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Buxton BF,
    2. Komeda M,
    3. Fuller JA,
    4. Gordon I
    . Bilateral internal thoracic artery grafting may improve outcome of coronary artery surgery. Risk-adjusted survival. Circulation. 1998;98(19 suppl):II1–II6.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Banning AP,
    2. Westaby S,
    3. Morice MC,
    4. Kappetein AP,
    5. Mohr FW,
    6. Berti S,
    7. Glauber M,
    8. Kellett MA,
    9. Kramer RS,
    10. Leadley K,
    11. Dawkins KD,
    12. Serruys PW
    . Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010;55:1067–1075.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Nesto RW,
    2. Kowalchuk GJ
    . The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol. 1987;59:23C–30C.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Jahnke C,
    2. Nagel E,
    3. Gebker R,
    4. Kokocinski T,
    5. Kelle S,
    6. Manka R,
    7. Fleck E,
    8. Paetsch I
    . Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 2007;115:1769–1776.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Lockie T,
    2. Ishida M,
    3. Perera D,
    4. Chiribiri A,
    5. De Silva K,
    6. Kozerke S,
    7. Marber M,
    8. Nagel E,
    9. Rezavi R,
    10. Redwood S,
    11. Plein S
    . High-resolution magnetic resonance myocardial perfusion imaging at 3.0-Tesla to detect hemodynamically significant coronary stenoses as determined by fractional flow reserve. J Am Coll Cardiol. 2011;57:70–75.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Costa MA,
    2. Shoemaker S,
    3. Futamatsu H,
    4. Klassen C,
    5. Angiolillo DJ,
    6. Nguyen M,
    7. Siuciak A,
    8. Gilmore P,
    9. Zenni MM,
    10. Guzman L,
    11. Bass TA,
    12. Wilke N
    . Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. J Am Coll Cardiol. 2007;50:514–522.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation: Cardiovascular Interventions
June 2013, Volume 6, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Residual Ischemia After Revascularization in Multivessel Coronary Artery Disease
    Jayanth R. Arnold, Theodoros D. Karamitsos, William J. van Gaal, Luca Testa, Jane M. Francis, Paul Bhamra-Ariza, Ali Ali, Joseph B. Selvanayagam, Steve Westaby, Rana Sayeed, Michael Jerosch-Herold, Stefan Neubauer and Adrian P. Banning
    Circulation: Cardiovascular Interventions. 2013;6:237-245, originally published June 18, 2013
    https://doi.org/10.1161/CIRCINTERVENTIONS.112.000064

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation: Cardiovascular Interventions.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Residual Ischemia After Revascularization in Multivessel Coronary Artery Disease
    (Your Name) has sent you a message from Circulation: Cardiovascular Interventions
    (Your Name) thought you would like to see the Circulation: Cardiovascular Interventions web site.
  • Share on Social Media
    Residual Ischemia After Revascularization in Multivessel Coronary Artery Disease
    Jayanth R. Arnold, Theodoros D. Karamitsos, William J. van Gaal, Luca Testa, Jane M. Francis, Paul Bhamra-Ariza, Ali Ali, Joseph B. Selvanayagam, Steve Westaby, Rana Sayeed, Michael Jerosch-Herold, Stefan Neubauer and Adrian P. Banning
    Circulation: Cardiovascular Interventions. 2013;6:237-245, originally published June 18, 2013
    https://doi.org/10.1161/CIRCINTERVENTIONS.112.000064
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Imaging and Diagnostic Testing
    • Imaging
  • Intervention, Surgery, Transplantation
    • Cardiovascular Surgery

Circulation: Cardiovascular Interventions

  • About Circulation: Cardiovascular Interventions
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451 
email: circ@circulationjournal.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer
  • You're the Cure

Online Communities

  • AFib Support
  • Empowered to Serve
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured